Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Non Operating Investment Income (2023 - 2024)

Historic Non Operating Investment Income for Cartesian Therapeutics (RNAC) over the last 2 years, with Q1 2024 value amounting to -$6.9 million.

  • Cartesian Therapeutics' Non Operating Investment Income changed N/A to -$6.9 million in Q1 2024 from the same period last year, while for Dec 2024 it was -$6.9 million, marking a year-over-year increase of 9539.44%. This contributed to the annual value of -$6.9 million for FY2024, which is 9539.44% up from last year.
  • According to the latest figures from Q1 2024, Cartesian Therapeutics' Non Operating Investment Income is -$6.9 million.
  • Cartesian Therapeutics' 5-year Non Operating Investment Income high stood at -$6.9 million for Q1 2024, and its period low was -$149.6 million during Q4 2023.